---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-25-008877"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2025-07-09T23:59:59+00:00"
generated_at: "2026-05-18T08:52:15.158910+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Tonix Pharmaceuticals Announces Publication of Phase 3 RESILIENT Trial Data for TNX-102 SL

## Summary
- Full results from confirmatory Phase 3 RESILIENT trial of TNX-102 SL published online in Pain Medicine on July 9, 2025.
- TNX-102 SL achieved statistically significant improvement in primary endpoint of reducing fibromyalgia pain vs placebo (LS mean reduction 1.8 vs 1.2 points).
- Statistically significant improvements observed across all six prespecified key secondary endpoints.
- FDA PDUFA target date for TNX-102 SL is August 15, 2025; if approved, would be first new fibromyalgia drug in over 15 years.
- TNX-102 SL was generally well tolerated; most common AEs were mild oral tingling/numbness and aftertaste, no drug-related serious AEs.

## SEC filing metadata
- accession: 0001999371-25-008877
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2025-07-09T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937125008877/0001999371-25-008877-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937125008877/tnxp-8k_070925.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-25-008877
- JSON: https://secwatch.observer/filing/0001999371-25-008877.json
- Plain text: https://secwatch.observer/filing/0001999371-25-008877.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.